COMMUNIQUÉS West-GlobeNewswire
-
Spur Therapeutics Announces First Patient Dosed in GALILEO-3 Pivotal Clinical Trial of FLT201 for the Treatment of Gaucher Disease Type 1
07/07/2026 -
PDV MedTech and Corscience Announce Strategic Partnership to Advance MedTech Development and Manufacturing Across the US and Europe
07/07/2026 -
Amplia Announces Appointment of Brett Carter to Board
07/07/2026 -
Stipple Bio Appoints Biopharma Business Development Leader Roland Gendron as Chief Business Officer
07/07/2026 -
Digital Dental Lab Dandy Appoints Head of Product to Accelerate AI-Powered Innovation
07/07/2026 -
WELL Health Announces Proposed TSXV Listing and Concurrent Financing for WELLSTAR, One of Canada’s Leading Healthcare Software and AI Platforms
07/07/2026 -
Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway
07/07/2026 -
Press Release Biocartis NV: Biocartis and Discovery Life Sciences Announce Strategic Collaboration to Advance Precision Oncology Diagnostics
07/07/2026 -
Nu-Tek BioSciences Present Cell Nutrient Innovation, Raw Material Expertise at SIMB 2026
07/07/2026 -
Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board
07/07/2026 -
Applied Biologics Announces VA Federal Supply Schedule Contract Modification Supporting Long-Term Access to XWRAP®
07/07/2026 -
Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program
07/07/2026 -
Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization
07/07/2026 -
Cosmos Health Reports Preliminary Record Q2 and H1 2026 Revenue, Up Over 30% Year-Over-Year; Continues Open Market Share Repurchases
07/07/2026 -
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
07/07/2026 -
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling
07/07/2026 -
A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today’s Injectables Were Not Built to Fill
07/07/2026 -
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
07/07/2026 -
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
07/07/2026
Pages